Remit - To appraise the clinical and cost effectiveness of trastuzumab emtansine within its marketing authorisation for treating human epidermal growth factor receptor (HER2) positive breast cancer in the adjuvant setting
Status In progress
Process STA 2018
ID number 1516

Provisional Schedule

Committee meeting: 1 24 March 2020
Expected publication 10 June 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Key events during the development of the guidance:

Date Update
22 July 2019 Invitation to participate
10 May 2019 In progress, Referred 13 February 2019
21 March 2019 - 18 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance